Cysteine proteases in atherosclerosis

FEBS Journal

Volumn 284, Issue 10, 2017, Pages 1455-1472

  Weiss Sadan, Tommy ^a   Gotsman, Israel ^b   Blum, Galia ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

activity based probes; atherosclerosis; autophagy; cathepsins; cholesterol; metabolism; vascular inflammation

Indexed keywords

BIOLOGICAL MARKER; CATHEPSIN; LOW DENSITY LIPOPROTEIN RECEPTOR; CHOLESTEROL; CYSTEINE PROTEINASE;

ANGIOGENESIS; APOPTOSIS; ARTERIAL REMODELING; ATHEROGENESIS; ATHEROSCLEROSIS; AUTOPHAGY; BLOOD VESSEL; CELL DAMAGE; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME STRUCTURE; HEART DISEASE; HUMAN; INFLAMMATION; LIPID METABOLISM; LYSOSOME; MACROPHAGE; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; ANIMAL; ENZYMOLOGY; GENETICS; METABOLISM; PHYSIOLOGY;

ANIMALS; ATHEROSCLEROSIS; AUTOPHAGY; CATHEPSINS; CHOLESTEROL; CYSTEINE PROTEASES; HUMANS;

EID: 85014742453     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.14043     Document Type: Review

References (166)

1. Herrington W, Lacey B, Sherliker P, Armitage J & Lewington S (2016) Epidemiology of atherosclerosis and the potential to reduce the global burden of atherothrombotic disease. Circ Res 118, 535–546.
2. Tabas I, Garcia-Cardena G & Owens GK (2015) Recent insights into the cellular biology of atherosclerosis. J Cell Biol 209, 13–22.
3. Back M, Weber C & Lutgens E (2015) Regulation of atherosclerotic plaque inflammation. J Intern Med 278, 462–482.
4. Cascieri MA (2002) The potential for novel anti-inflammatory therapies for coronary artery disease. Nat Rev Drug Discov 1, 122–130.
5. Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352, 1685–1695.
6. Hansson GK, Libby P & Tabas I (2015) Inflammation and plaque vulnerability. J Intern Med 278, 483–493.
7. Newby AC (2014) Proteinases and plaque rupture: unblocking the road to translation. Curr Opin Lipidol 25, 358–366.
8. Stoka V, Turk V & Turk B (2016) Lysosomal cathepsins and their regulation in aging and neurodegeneration. Ageing Res Rev 32, 22–37.
9. Turk V, Turk B & Turk D (2001) Lysosomal cysteine proteases: facts and opportunities. EMBO J 20, 4629–4633.
10. Turk V, Stoka V, Vasiljeva O, Renko M, Sun T, Turk B & Turk D (2012) Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochim Biophys Acta 1824, 68–88.
11. Turk D, Janjic V, Stern I, Podobnik M, Lamba D, Dahl SW, Lauritzen C, Pedersen J, Turk V & Turk B (2001) Structure of human dipeptidyl peptidase I (cathepsin C): exclusion domain added to an endopeptidase framework creates the machine for activation of granular serine proteases. EMBO J 20, 6570–6582.
12. Turk B & Turk V (2009) Lysosomes as “suicide bags” in cell death: myth or reality? J Biol Chem 284, 21783–21787.
13. Brix K, Dunkhorst A, Mayer K & Jordans S (2008) Cysteine cathepsins: cellular roadmap to different functions. Biochimie 90, 194–207.
14. Wex T, Buhling F, Wex H, Gunther D, Malfertheiner P, Weber E & Bromme D (2001) Human cathepsin W, a cysteine protease predominantly expressed in NK cells, is mainly localized in the endoplasmic reticulum. J Immunol 167, 2172–2178.
15. Vizovisek M, Vidmar R, Van Quickelberghe E, Impens F, Andjelkovic U, Sobotic B, Stoka V, Gevaert K, Turk B & Fonovic M (2015) Fast profiling of protease specificity reveals similar substrate specificities for cathepsins K, L and S. Proteomics 15, 2479–2490.
16. Biniossek ML, Nagler DK, Becker-Pauly C & Schilling O (2011) Proteomic identification of protease cleavage sites characterizes prime and non-prime specificity of cysteine cathepsins B, L, and S. J Proteome Res 10, 5363–5373.
17. Choe Y, Leonetti F, Greenbaum DC, Lecaille F, Bogyo M, Bromme D, Ellman JA & Craik CS (2006) Substrate profiling of cysteine proteases using a combinatorial peptide library identifies functionally unique specificities. J Biol Chem 281, 12824–12832.
18. Tamhane T, Lllukkumbura R, Lu S, Maelandsmo GM, Haugen MH & Brix K (2016) Nuclear cathepsin L activity is required for cell cycle progression of colorectal carcinoma cells. Biochimie 122, 208–218.
19. Turk B & Stoka V (2007) Protease signalling in cell death: caspases versus cysteine cathepsins. FEBS Lett 581, 2761–2767.
20. Potts W, Bowyer J, Jones H, Tucker D, Freemont AJ, Millest A, Martin C, Vernon W, Neerunjun D, Slynn G et al. (2004) Cathepsin L-deficient mice exhibit abnormal skin and bone development and show increased resistance to osteoporosis following ovariectomy. Int J Exp Pathol 85, 85–96.
21. Stypmann J, Glaser K, Roth W, Tobin DJ, Petermann I, Matthias R, Monnig G, Haverkamp W, Breithardt G, Schmahl W et al. (2002) Dilated cardiomyopathy in mice deficient for the lysosomal cysteine peptidase cathepsin L. Proc Natl Acad Sci U S A 99, 6234–6239.
22. Olson OC & Joyce JA (2015) Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response. Nat Rev Cancer 15, 712–729.
23. Reiser J, Adair B & Reinheckel T (2010) Specialized roles for cysteine cathepsins in health and disease. J Clin Invest 120, 3421–3431.
24. Salpeter SJ & Blum G (2013) Ready, set, cleave: proteases in action. Chem Biol 20, 137–138.
25. Jerala R, Zerovnik E, Kidric J & Turk V (1998) pH-induced conformational transitions of the propeptide of human cathepsin L. A role for a molten globule state in zymogen activation. J Biol Chem 273, 11498–11504.
26. Stoka V, Turk B & Turk V (2005) Lysosomal cysteine proteases: structural features and their role in apoptosis. IUBMB Life 57, 347–353.
27. Cavallo-Medved D, Rudy D, Blum G, Bogyo M, Caglic D & Sloane BF (2009) Live-cell imaging demonstrates extracellular matrix degradation in association with active cathepsin B in caveolae of endothelial cells during tube formation. Exp Cell Res 315, 1234–1246.
28. Repnik U, Starr AE, Overall CM & Turk B (2015) Cysteine cathepsins activate ELR chemokines and inactivate non-ELR chemokines. J Biol Chem 290, 13800–13811.
29. Mohamed MM & Sloane BF (2006) Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 6, 764–775.
30. Sobotic B, Vizovisek M, Vidmar R, Van Damme P, Gocheva V, Joyce JA, Gevaert K, Turk V, Turk B & Fonovic M (2015) Proteomic identification of cysteine cathepsin substrates shed from the surface of cancer cells. Mol Cell Proteomics 14, 2213–2228.
31. Novinec M, Lenarcic B & Turk B (2014) Cysteine cathepsin activity regulation by glycosaminoglycans. Biomed Res Int 2014, 309718.
32. Lafarge JC, Naour N, Clement K & Guerre-Millo M (2010) Cathepsins and cystatin C in atherosclerosis and obesity. Biochimie 92, 1580–1586.
33. Turk V, Stoka V & Turk D (2008) Cystatins: biochemical and structural properties, and medical relevance. Front Biosci 13, 5406–5420.
34. Vray B, Hartmann S & Hoebeke J (2002) Immunomodulatory properties of cystatins. Cell Mol Life Sci 59, 1503–1512.
35. Kopitar-Jerala N (2006) The role of cystatins in cells of the immune system. FEBS Lett 580, 6295–6301.
36. Shi GP, Sukhova GK, Grubb A, Ducharme A, Rhode LH, Lee RT, Ridker PM, Libby P & Chapman HA (1999) Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest 104, 1191–1197.
37. Bengtsson E, To F, Grubb A, Hakansson K, Wittgren L, Nilsson J & Jovinge S (2005) Absence of the protease inhibitor cystatin C in inflammatory cells results in larger plaque area in plaque regression of apoE-deficient mice. Atherosclerosis 180, 45–53.
38. Weitoft T, Larsson A, Manivel VA, Lysholm J, Knight A & Ronnelid J (2015) Cathepsin S and cathepsin L in serum and synovial fluid in rheumatoid arthritis with and without autoantibodies. Rheumatology (Oxford) 54, 1923–1928.
39. Lutgens SP, Cleutjens KB, Daemen MJ & Heeneman S (2007) Cathepsin cysteine proteases in cardiovascular disease. FASEB J 21, 3029–3041.
40. Liu J, Sukhova GK, Yang JT, Sun J, Ma L, Ren A, Xu WH, Fu H, Dolganov GM, Hu C et al. (2006) Cathepsin L expression and regulation in human abdominal aortic aneurysm, atherosclerosis, and vascular cells. Atherosclerosis 184, 302–311.
41. Sukhova GK, Shi GP, Simon DI, Chapman HA & Libby P (1998) Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest 102, 576–583.
42. Platt MO, Ankeny RF, Shi GP, Weiss D, Vega JD, Taylor WR & Jo H (2007) Expression of cathepsin K is regulated by shear stress in cultured endothelial cells and is increased in endothelium in human atherosclerosis. Am J Physiol Heart Circ Physiol 292, H1479–H1486.
43. Stellos K, Gatsiou A, Stamatelopoulos K, Perisic Matic L, John D, Lunella FF, Jae N, Rossbach O, Amrhein C, Sigala F et al. (2016) Adenosine-to-inosine RNA editing controls cathepsin S expression in atherosclerosis by enabling HuR-mediated post-transcriptional regulation. Nat Med 22, 1140–1150.
44. Jormsjo S, Wuttge DM, Sirsjo A, Whatling C, Hamsten A, Stemme S & Eriksson P (2002) Differential expression of cysteine and aspartic proteases during progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol 161, 939–945.
45. Kitamoto S, Sukhova GK, Sun J, Yang M, Libby P, Love V, Duramad P, Sun C, Zhang Y, Yang X et al. (2007) Cathepsin L deficiency reduces diet-induced atherosclerosis in low-density lipoprotein receptor-knockout mice. Circulation 115, 2065–2075.
46. Sukhova GK, Zhang Y, Pan JH, Wada Y, Yamamoto T, Naito M, Kodama T, Tsimikas S, Witztum JL, Lu ML et al. (2003) Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. J Clin Invest 111, 897–906.
47. de Duve C (2005) The lysosome turns fifty. Nat Cell Biol 7, 847–849.
48. Efeyan A, Comb WC & Sabatini DM (2015) Nutrient-sensing mechanisms and pathways. Nature 517, 302–310.
49. Appelqvist H, Waster P, Kagedal K & Ollinger K (2013) The lysosome: from waste bag to potential therapeutic target. J Mol Cell Biol 5, 214–226.
50. Cuervo AM (2004) Autophagy: in sickness and in health. Trends Cell Biol 14, 70–77.
51. Saftig P & Klumperman J (2009) Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function. Nat Rev Mol Cell Biol 10, 623–635.
52. Settembre C & Ballabio A (2014) Lysosomal adaptation: how the lysosome responds to external cues. Cold Spring Harb Perspect Biol 6, 1–15.
53. Sergin I, Evans TD & Razani B (2015) Degradation and beyond: the macrophage lysosome as a nexus for nutrient sensing and processing in atherosclerosis. Curr Opin Lipidol 26, 394–404.
54. Jessup W & Kritharides L (2000) Metabolism of oxidized LDL by macrophages. Curr Opin Lipidol 11, 473–481.
55. Brown MS & Goldstein JL (1998) Sterol regulatory element binding proteins (SREBPs): controllers of lipid synthesis and cellular uptake. Nutr Rev 56, S1–S3; discussion S54–S75.
56. Das A, Brown MS, Anderson DD, Goldstein JL & Radhakrishnan A (2014) Three pools of plasma membrane cholesterol and their relation to cholesterol homeostasis. Elife 3, 1–16.
57. Maxfield FR & Tabas I (2005) Role of cholesterol and lipid organization in disease. Nature 438, 612–621.
58. Oorni K, Pentikainen MO, Ala-Korpela M & Kovanen PT (2000) Aggregation, fusion, and vesicle formation of modified low density lipoprotein particles: molecular mechanisms and effects on matrix interactions. J Lipid Res 41, 1703–1714.
59. Glass CK & Witztum JL (2001) Atherosclerosis. the road ahead. Cell 104, 503–516.
60. Christ A & Latz E (2014) LOX-1 and mitochondria: an inflammatory relationship. Cardiovasc Res 103, 435–437.
61. Canton J, Neculai D & Grinstein S (2013) Scavenger receptors in homeostasis and immunity. Nat Rev Immunol 13, 621–634.
62. Oorni K, Sneck M, Bromme D, Pentikainen MO, Lindstedt KA, Mayranpaa M, Aitio H & Kovanen PT (2004) Cysteine protease cathepsin F is expressed in human atherosclerotic lesions, is secreted by cultured macrophages, and modifies low density lipoprotein particles in vitro. J Biol Chem 279, 34776–34784.
63. Han SR, Momeni A, Strach K, Suriyaphol P, Fenske D, Paprotka K, Hashimoto SI, Torzewski M, Bhakdi S & Husmann M (2003) Enzymatically modified LDL induces cathepsin H in human monocytes: potential relevance in early atherogenesis. Arterioscler Thromb Vasc Biol 23, 661–667.
64. Brown AJ, Mander EL, Gelissen IC, Kritharides L, Dean RT & Jessup W (2000) Cholesterol and oxysterol metabolism and subcellular distribution in macrophage foam cells. Accumulation of oxidized esters in lysosomes. J Lipid Res 41, 226–237.
65. Linke M, Gordon RE, Brillard M, Lecaille F, Lalmanach G & Bromme D (2006) Degradation of apolipoprotein B-100 by lysosomal cysteine cathepsins. Biol Chem 387, 1295–1303.
66. Harmon GS, Lam MT & Glass CK (2011) PPARs and lipid ligands in inflammation and metabolism. Chem Rev 111, 6321–6340.
67. Ouimet M & Marcel YL (2012) Regulation of lipid droplet cholesterol efflux from macrophage foam cells. Arterioscler Thromb Vasc Biol 32, 575–581.
68. Ikonen E (2008) Cellular cholesterol trafficking and compartmentalization. Nat Rev Mol Cell Biol 9, 125–138.
69. Lee SD & Tontonoz P (2015) Liver X receptors at the intersection of lipid metabolism and atherogenesis. Atherosclerosis 242, 29–36.
70. Ouimet M, Franklin V, Mak E, Liao X, Tabas I & Marcel YL (2011) Autophagy regulates cholesterol efflux from macrophage foam cells via lysosomal acid lipase. Cell Metab 13, 655–667.
71. Haidar B, Kiss RS, Sarov-Blat L, Brunet R, Harder C, McPherson R & Marcel YL (2006) Cathepsin D, a lysosomal protease, regulates ABCA1-mediated lipid efflux. J Biol Chem 281, 39971–39981.
72. Becker L, Gharib SA, Irwin AD, Wijsman E, Vaisar T, Oram JF & Heinecke JW (2010) A macrophage sterol-responsive network linked to atherogenesis. Cell Metab 11, 125–135.
73. Lougheed M, Zhang HF & Steinbrecher UP (1991) Oxidized low density lipoprotein is resistant to cathepsins and accumulates within macrophages. J Biol Chem 266, 14519–14525.
74. Dhaliwal BS & Steinbrecher UP (2000) Cholesterol delivered to macrophages by oxidized low density lipoprotein is sequestered in lysosomes and fails to efflux normally. J Lipid Res 41, 1658–1665.
75. Li W, Yuan XM, Olsson AG & Brunk UT (1998) Uptake of oxidized LDL by macrophages results in partial lysosomal enzyme inactivation and relocation. Arterioscler Thromb Vasc Biol 18, 177–184.
76. O'Neil J, Hoppe G & Hoff HF (2003) Phospholipids in oxidized low density lipoproteins perturb the ability of macrophages to degrade internalized macromolecules and reduce intracellular cathepsin B activity. Atherosclerosis 169, 215–224.
77. O'Neil J, Hoppe G, Sayre LM & Hoff HF (1997) Inactivation of cathepsin B by oxidized LDL involves complex formation induced by binding of putative reactive sites exposed at low pH to thiols on the enzyme. Free Radic Biol Med 23, 215–225.
78. Crabb JW, O'Neil J, Miyagi M, West K & Hoff HF (2002) Hydroxynonenal inactivates cathepsin B by forming Michael adducts with active site residues. Protein Sci 11, 831–840.
79. Lindstedt L, Lee M, Oorni K, Bromme D & Kovanen PT (2003) Cathepsins F and S block HDL3-induced cholesterol efflux from macrophage foam cells. Biochem Biophys Res Commun 312, 1019–1024.
80. Dinnes DL, White MY, Kockx M, Traini M, Hsieh V, Kim MJ, Hou L, Jessup W, Rye KA, Thaysen-Andersen M et al. (2016) Human macrophage cathepsin B-mediated C-terminal cleavage of apolipoprotein A-I at Ser228 severely impairs antiatherogenic capacity. FASEB J 30, 4239–4255.
81. Gotsman I, Sharpe AH & Lichtman AH (2008) T-cell costimulation and coinhibition in atherosclerosis. Circ Res 103, 1220–1231.
82. Moore KJ & Tabas I (2011) Macrophages in the pathogenesis of atherosclerosis. Cell 145, 341–355.
83. Hoppe G, O'Neil J & Hoff HF (1994) Inactivation of lysosomal proteases by oxidized low density lipoprotein is partially responsible for its poor degradation by mouse peritoneal macrophages. J Clin Invest 94, 1506–1512.
84. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, Abela GS, Franchi L, Nunez G, Schnurr M et al. (2010) NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464, 1357–1361.
85. Stewart CR, Stuart LM, Wilkinson K, van Gils JM, Deng J, Halle A, Rayner KJ, Boyer L, Zhong R, Frazier WA et al. (2010) CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol 11, 155–161.
86. Sheedy FJ, Grebe A, Rayner KJ, Kalantari P, Ramkhelawon B, Carpenter SB, Becker CE, Ediriweera HN, Mullick AE, Golenbock DT et al. (2013) CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat Immunol 14, 812–820.
87. Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL, Fitzgerald KA & Latz E (2008) Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 9, 847–856.
88. Orlowski GM, Colbert JD, Sharma S, Bogyo M, Robertson SA & Rock KL (2015) Multiple cathepsins promote Pro-IL-1beta synthesis and NLRP3-mediated IL-1beta activation. J Immunol 195, 1685–1697.
89. Zhong Z, Umemura A, Sanchez-Lopez E, Liang S, Shalapour S, Wong J, He F, Boassa D, Perkins G, Ali SR et al. (2016) NF-kappaB restricts inflammasome activation via elimination of damaged mitochondria. Cell 164, 896–910.
90. Razani B, Feng C, Coleman T, Emanuel R, Wen H, Hwang S, Ting JP, Virgin HW, Kastan MB & Semenkovich CF (2012) Autophagy links inflammasomes to atherosclerotic progression. Cell Metab 15, 534–544.
91. Dennemarker J, Lohmuller T, Muller S, Aguilar SV, Tobin DJ, Peters C & Reinheckel T (2010) Impaired turnover of autophagolysosomes in cathepsin L deficiency. Biol Chem 391, 913–922.
92. Pan L, Li Y, Jia L, Qin Y, Qi G, Cheng J, Qi Y, Li H & Du J (2012) Cathepsin S deficiency results in abnormal accumulation of autophagosomes in macrophages and enhances Ang II-induced cardiac inflammation. PLoS One 7, e35315.
93. Emanuel R, Sergin I, Bhattacharya S, Turner JN, Epelman S, Settembre C, Diwan A, Ballabio A & Razani B (2014) Induction of lysosomal biogenesis in atherosclerotic macrophages can rescue lipid-induced lysosomal dysfunction and downstream sequelae. Arterioscler Thromb Vasc Biol 34, 1942–1952.
94. Sun M, Tian X, Liu Y, Zhu N, Li Y, Yang G, Peng C, Yan C & Han Y (2015) Cellular repressor of E1A-stimulated genes inhibits inflammation to decrease atherosclerosis in ApoE(–/–) mice. J Mol Cell Cardiol 86, 32–41.
95. Seimon T & Tabas I (2009) Mechanisms and consequences of macrophage apoptosis in atherosclerosis. J Lipid Res 50 (Suppl), S382–S387.
96. Paramel Varghese G, Folkersen L, Strawbridge RJ, Halvorsen B, Yndestad A, Ranheim T, Krohg-Sorensen K, Skjelland M, Espevik T, Aukrust P et al. (2016) NLRP3 inflammasome expression and activation in human atherosclerosis. J Am Heart Assoc 5, 1–11.
97. Jacobson LS, Lima H Jr, Goldberg MF, Gocheva V, Tsiperson V, Sutterwala FS, Joyce JA, Gapp BV, Blomen VA, Chandran K et al. (2013) Cathepsin-mediated necrosis controls the adaptive immune response by Th2 (T helper type 2)-associated adjuvants. J Biol Chem 288, 7481–7491.
98. Brojatsch J, Lima H Jr, Palliser D, Jacobson LS, Muehlbauer SM, Furtado R, Goldman DL, Lisanti MP & Chandran K (2015) Distinct cathepsins control necrotic cell death mediated by pyroptosis inducers and lysosome-destabilizing agents. Cell Cycle 14, 964–972.
99. Tabas I (2016) Heart disease: death-defying plaque cells. Nature 536, 32–33.
100. Tabas I (2005) Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Arterioscler Thromb Vasc Biol 25, 2255–2264.
101. Guicciardi ME, Deussing J, Miyoshi H, Bronk SF, Svingen PA, Peters C, Kaufmann SH & Gores GJ (2000) Cathepsin B contributes to TNF-alpha-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. J Clin Invest 106, 1127–1137.
102. Feldstein AE, Werneburg NW, Canbay A, Guicciardi ME, Bronk SF, Rydzewski R, Burgart LJ & Gores GJ (2004) Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 40, 185–194.
103. Li W & Yuan XM (2004) Increased expression and translocation of lysosomal cathepsins contribute to macrophage apoptosis in atherogenesis. Ann N Y Acad Sci 1030, 427–433.
104. Wakita K, Morita SY, Okamoto N, Takata E, Handa T & Nakano M (2015) Chylomicron remnant model emulsions induce intracellular cholesterol accumulation and cell death due to lysosomal destabilization. Biochim Biophys Acta 1851, 598–604.
105. Li W, Dalen H, Eaton JW & Yuan XM (2001) Apoptotic death of inflammatory cells in human atheroma. Arterioscler Thromb Vasc Biol 21, 1124–1130.
106. Li W, Kornmark L, Jonasson L, Forssell C & Yuan XM (2009) Cathepsin L is significantly associated with apoptosis and plaque destabilization in human atherosclerosis. Atherosclerosis 202, 92–102.
107. Cai B, Thorp EB, Doran AC, Subramanian M, Sansbury BE, Lin CS, Spite M, Fredman G & Tabas I (2016) MerTK cleavage limits proresolving mediator biosynthesis and exacerbates tissue inflammation. Proc Natl Acad Sci U S A 113, 6526–6531.
108. Kojima Y, Volkmer JP, McKenna K, Civelek M, Lusis AJ, Miller CL, Direnzo D, Nanda V, Ye J, Connolly AJ et al. (2016) CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature 536, 86–90.
109. Liao X, Sluimer JC, Wang Y, Subramanian M, Brown K, Pattison JS, Robbins J, Martinez J & Tabas I (2012) Macrophage autophagy plays a protective role in advanced atherosclerosis. Cell Metab 15, 545–553.
110. Xu M, Liu Y, Zhao L, Gan Q, Wang X & Yang C (2014) The lysosomal cathepsin protease CPL-1 plays a leading role in phagosomal degradation of apoptotic cells in Caenorhabditis elegans. Mol Biol Cell 25, 2071–2083.
111. Libby P, Ridker PM & Hansson GK (2011) Progress and challenges in translating the biology of atherosclerosis. Nature 473, 317–325.
112. Fonovic M & Turk B (2014) Cysteine cathepsins and extracellular matrix degradation. Biochim Biophys Acta 1840, 2560–2570.
113. Panwar P, Du X, Sharma V, Lamour G, Castro M, Li H & Bromme D (2013) Effects of cysteine proteases on the structural and mechanical properties of collagen fibers. J Biol Chem 288, 5940–5950.
114. Li Z, Hou WS, Escalante-Torres CR, Gelb BD & Bromme D (2002) Collagenase activity of cathepsin K depends on complex formation with chondroitin sulfate. J Biol Chem 277, 28669–28676.
115. Aguda AH, Panwar P, Du X, Nguyen NT, Brayer GD & Bromme D (2014) Structural basis of collagen fiber degradation by cathepsin K. Proc Natl Acad Sci U S A 111, 17474–17479.
116. Lecaille F, Choe Y, Brandt W, Li Z, Craik CS & Bromme D (2002) Selective inhibition of the collagenolytic activity of human cathepsin K by altering its S2 subsite specificity. Biochemistry 41, 8447–8454.
117. Yasuda Y, Li Z, Greenbaum D, Bogyo M, Weber E & Bromme D (2004) Cathepsin V, a novel and potent elastolytic activity expressed in activated macrophages. J Biol Chem 279, 36761–36770.
118. Du X, Chen NL, Wong A, Craik CS & Bromme D (2013) Elastin degradation by cathepsin V requires two exosites. J Biol Chem 288, 34871–34881.
119. Liu J, Sukhova GK, Sun JS, Xu WH, Libby P & Shi GP (2004) Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol 24, 1359–1366.
120. Sun J, Sukhova GK, Wolters PJ, Yang M, Kitamoto S, Libby P, MacFarlane LA, Mallen-St Clair J & Shi GP (2007) Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat Med 13, 719–724.
121. Samokhin AO, Lythgo PA, Gauthier JY, Percival MD & Bromme D (2010) Pharmacological inhibition of cathepsin S decreases atherosclerotic lesions in Apoe–/– mice. J Cardiovasc Pharmacol 56, 98–105.
122. de Nooijer R, Bot I, von der Thusen JH, Leeuwenburgh MA, Overkleeft HS, Kraaijeveld AO, Dorland R, van Santbrink PJ, van Heiningen SH, Westra MM et al. (2009) Leukocyte cathepsin S is a potent regulator of both cell and matrix turnover in advanced atherosclerosis. Arterioscler Thromb Vasc Biol 29, 188–194.
123. Lutgens E, Lutgens SP, Faber BC, Heeneman S, Gijbels MM, de Winther MP, Frederik P, van der Made I, Daugherty A, Sijbers AM et al. (2006) Disruption of the cathepsin K gene reduces atherosclerosis progression and induces plaque fibrosis but accelerates macrophage foam cell formation. Circulation 113, 98–107.
124. Guo J, Bot I, de Nooijer R, Hoffman SJ, Stroup GB, Biessen EA, Benson GM, Groot PH, Van Eck M & Van Berkel TJ (2009) Leucocyte cathepsin K affects atherosclerotic lesion composition and bone mineral density in low-density lipoprotein receptor deficient mice. Cardiovasc Res 81, 278–285.
125. Barascuk N, Skjot-Arkil H, Register TC, Larsen L, Byrjalsen I, Christiansen C & Karsdal MA (2010) Human macrophage foam cells degrade atherosclerotic plaques through cathepsin K mediated processes. BMC Cardiovasc Disord 10, 19.
126. Xu J, Lu X & Shi GP (2015) Vasa vasorum in atherosclerosis and clinical significance. Int J Mol Sci 16, 11574–11608.
127. Moulton KS, Vakili K, Zurakowski D, Soliman M, Butterfield C, Sylvin E, Lo KM, Gillies S, Javaherian K & Folkman J (2003) Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci U S A 100, 4736–4741.
128. Silvestre-Roig C, de Winther MP, Weber C, Daemen MJ, Lutgens E & Soehnlein O (2014) Atherosclerotic plaque destabilization: mechanisms, models, and therapeutic strategies. Circ Res 114, 214–226.
129. de Vries MR & Quax PH (2016) Plaque angiogenesis and its relation to inflammation and atherosclerotic plaque destabilization. Curr Opin Lipidol 27, 499–506.
130. Shi GP, Sukhova GK, Kuzuya M, Ye Q, Du J, Zhang Y, Pan JH, Lu ML, Cheng XW, Iguchi A et al. (2003) Deficiency of the cysteine protease cathepsin S impairs microvessel growth. Circ Res 92, 493–500.
131. Wang B, Sun J, Kitamoto S, Yang M, Grubb A, Chapman HA, Kalluri R & Shi GP (2006) Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. J Biol Chem 281, 6020–6029.
132. Li X, Cheng XW, Hu L, Wu H, Guo P, Hao CN, Jiang H, Zhu E, Huang Z, Inoue A et al. (2015) Cathepsin S activity controls ischemia-induced neovascularization in mice. Int J Cardiol 183, 198–208.
133. Wu H, Cheng XW, Hu L, Takeshita K, Hu C, Du Q, Li X, Zhu E, Huang Z, Yisireyili M et al. (2016) Cathepsin S activity controls injury-related vascular repair in mice via the TLR2-mediated p38MAPK and PI3K-Akt/p-HDAC6 Signaling pathway. Arterioscler Thromb Vasc Biol 36, 1549–1557.
134. Urbich C, Heeschen C, Aicher A, Sasaki K, Bruhl T, Farhadi MR, Vajkoczy P, Hofmann WK, Peters C, Pennacchio LA et al. (2005) Cathepsin L is required for endothelial progenitor cell-induced neovascularization. Nat Med 11, 206–213.
135. Hu L, Cheng XW, Song H, Inoue A, Jiang H, Li X, Shi GP, Kozawa E, Okumura K & Kuzuya M (2014) Cathepsin K activity controls injury-related vascular repair in mice. Hypertension 63, 607–615.
136. Jiang H, Cheng XW, Shi GP, Hu L, Inoue A, Yamamura Y, Wu H, Takeshita K, Li X, Huang Z et al. (2014) Cathepsin K-mediated Notch1 activation contributes to neovascularization in response to hypoxia. Nat Commun 5, 3838.
137. Perisic L, Aldi S, Sun Y, Folkersen L, Razuvaev A, Roy J, Lengquist M, Akesson S, Wheelock CE, Maegdefessel L et al. (2016) Gene expression signatures, pathways and networks in carotid atherosclerosis. J Intern Med 279, 293–308.
138. Abd-Elrahman I, Meir K, Kosuge H, Ben-Nun Y, Weiss Sadan T, Rubinstein C, Samet Y, McConnell MV & Blum G (2016) Characterizing cathepsin activity and macrophage subtypes in excised human carotid plaques. Stroke 47, 1101–1108.
139. Goncalves I, den Ruijter H, Nahrendorf M & Pasterkamp G (2015) Detecting the vulnerable plaque in patients. J Intern Med 278, 520–530.
140. Li H, O'Donoghue AJ, van der Linden WA, Xie SC, Yoo E, Foe IT, Tilley L, Craik CS, da Fonseca PC & Bogyo M (2016) Structure- and function-based design of Plasmodium-selective proteasome inhibitors. Nature 530, 233–236.
141. Blum G (2008) Use of fluorescent imaging to investigate pathological protease activity. Curr Opin Drug Discov Devel 11, 708–716.
142. Jaffer FA, Libby P & Weissleder R (2007) Molecular imaging of cardiovascular disease. Circulation 116, 1052–1061.
143. Hughes CS, Burden RE, Gilmore BF & Scott CJ (2016) Strategies for detection and quantification of cysteine cathepsins-evolution from bench to bedside. Biochimie 122, 48–61.
144. Edgington LE, Verdoes M & Bogyo M (2011) Functional imaging of proteases: recent advances in the design and application of substrate-based and activity-based probes. Curr Opin Chem Biol 15, 798–805.
145. Weissleder R, Tung CH, Mahmood U & Bogdanov A Jr (1999) In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol 17, 375–378.
146. Chen J, Tung CH, Mahmood U, Ntziachristos V, Gyurko R, Fishman MC, Huang PL & Weissleder R (2002) In vivo imaging of proteolytic activity in atherosclerosis. Circulation 105, 2766–2771.
147. Jaffer FA, Kim DE, Quinti L, Tung CH, Aikawa E, Pande AN, Kohler RH, Shi GP, Libby P & Weissleder R (2007) Optical visualization of cathepsin K activity in atherosclerosis with a novel, protease-activatable fluorescence sensor. Circulation 115, 2292–2298.
148. Jaffer FA, Vinegoni C, John MC, Aikawa E, Gold HK, Finn AV, Ntziachristos V, Libby P & Weissleder R (2008) Real-time catheter molecular sensing of inflammation in proteolytically active atherosclerosis. Circulation 118, 1802–1809.
149. Lin SA, Patel M, Suresch D, Connolly B, Bao B, Groves K, Rajopadhye M, Peterson JD, Klimas M, Sur C et al. (2012) Quantitative longitudinal imaging of vascular inflammation and treatment by ezetimibe in apoE mice by FMT using new optical imaging biomarkers of cathepsin activity and alpha(v)beta(3) integrin. Int J Mol Imaging 2012, 189254.
150. Blum G, Weimer RM, Edgington LE, Adams W & Bogyo M (2009) Comparative assessment of substrates and activity based probes as tools for non-invasive optical imaging of cysteine protease activity. PLoS One 4, e6374.
151. Hu HY, Vats D, Vizovisek M, Kramer L, Germanier C, Wendt KU, Rudin M, Turk B, Plettenburg O & Schultz C (2014) In vivo imaging of mouse tumors by a lipidated cathepsin S substrate. Angew Chem Int Ed Engl 53, 7669–7673.
152. Blum G, Mullins SR, Keren K, Fonovic M, Jedeszko C, Rice MJ, Sloane BF & Bogyo M (2005) Dynamic imaging of protease activity with fluorescently quenched activity-based probes. Nat Chem Biol 1, 203–209.
153. Blum G, von Degenfeld G, Merchant MJ, Blau HM & Bogyo M (2007) Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes. Nat Chem Biol 3, 668–677.
154. Abd-Elrahman I, Kosuge H, Wises Sadan T, Ben-Nun Y, Meir K, Rubinstein C, Bogyo M, McConnell MV & Blum G (2016) Cathepsin activity-based probes and inhibitor for preclinical atherosclerosis imaging and macrophage depletion. PLoS One 11, e0160522.
155. Garland M, Yim JJ & Bogyo M (2016) A bright future for precision medicine: advances in fluorescent chemical probe design and their clinical application. Cell Chem Biol 23, 122–136.
156. Ren G, Blum G, Verdoes M, Liu H, Syed S, Edgington LE, Gheysens O, Miao Z, Jiang H, Gambhir SS et al. (2011) Non-invasive imaging of cysteine cathepsin activity in solid tumors using a 64Cu-labeled activity-based probe. PLoS One 6, e28029.
157. Withana NP, Saito T, Ma X, Garland M, Liu C, Kosuge H, Amsallem M, Verdoes M, Ofori LO, Fischbein M et al. (2016) Dual-modality activity-based probes as molecular imaging agents for vascular inflammation. J Nucl Med 57, 1583–1590.
158. Withana NP, Ma X, McGuire HM, Verdoes M, van der Linden WA, Ofori LO, Zhang R, Li H, Sanman LE, Wei K et al. (2016) Non-invasive imaging of idiopathic pulmonary fibrosis using cathepsin protease probes. Sci Rep 6, 19755.
159. Tarkin JM, Dweck MR, Evans NR, Takx RA, Brown AJ, Tawakol A, Fayad ZA & Rudd JH (2016) Imaging atherosclerosis. Circ Res 118, 750–769.
160. Figueiredo JL, Aikawa M, Zheng C, Aaron J, Lax L, Libby P, de Lima Filho JL, Gruener S, Fingerle J, Haap W et al. (2015) Selective cathepsin S inhibition attenuates atherosclerosis in apolipoprotein E-deficient mice with chronic renal disease. Am J Pathol 185, 1156–1166.
161. Waksman R, McEwan PE, Moore TI, Pakala R, Kolodgie FD, Hellinga DG, Seabron RC, Rychnovsky SJ, Vasek J, Scott RW et al. (2008) PhotoPoint photodynamic therapy promotes stabilization of atherosclerotic plaques and inhibits plaque progression. J Am Coll Cardiol 52, 1024–1032.
162. Ben-Nun Y, Merquiol E, Brandis A, Turk B, Scherz A & Blum G (2015) Photodynamic quenched cathepsin activity based probes for cancer detection and macrophage targeted therapy. Theranostics 5, 847–862.
163. Shon SM, Choi Y, Kim JY, Lee DK, Park JY, Schellingerhout D & Kim DE (2013) Photodynamic therapy using a protease-mediated theranostic agent reduces cathepsin-B activity in mouse atheromata in vivo. Arterioscler Thromb Vasc Biol 33, 1360–1365.
164. Mullard A (2016) Merck & Co. drops osteoporosis drug odanacatib. Nat Rev Drug Discov 15, 669.
165. Prudova A, Gocheva V, Auf dem Keller U, Eckhard U, Olson OC, Akkari L, Butler GS, Fortelny N, Lange PF, Mark JC et al. (2016) TAILS N-terminomics and proteomics show protein degradation dominates over proteolytic processing by cathepsins in pancreatic tumors. Cell Rep 16, 1762–1773.
166. Guncar G, Pungercic G, Klemencic I, Turk V & Turk D (1999) Crystal structure of MHC class II-associated p41 Ii fragment bound to cathepsin L reveals the structural basis for differentiation between cathepsins L and S. EMBO J 18, 793–803.